A phase II clinical trial (NCT02671435) of the combination of anti-NKG2A mAbs and anti-PD-1 mAbs showed encouraging results for patients with CRC, particularly those resistance to therapy with anti-PD-1/PD-L1 mAbs (113). Here, CD274 is linked to colorectal carcinoma.